C9orf72 and frontotemporal dementia: With anticipated progress in the development of therapies targeting genetic causes of ALS and FTD and the enthusiasm for prevention trials in the unaffected C9orf72 repeat expansion carrier population, now is the time to begin work on the design of a prevention trial in this population.